NCT03950609View on ClinicalTrials.gov

Lenvatinib and Everolimus in Treating Patients With Advanced, Unresectable Carcinoid Tumors

PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 30, 2019

Primary Completion Date

March 30, 2026

Study Completion Date

March 30, 2026

Conditions

Advanced Carcinoid TumorDigestive System Neuroendocrine NeoplasmMultiple Endocrine Neoplasia Type 1Neuroendocrine NeoplasmUnresectable Carcinoid Tumor

Interventions

DRUG

Everolimus

Given PO

DRUG

Lenvatinib

Given PO

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER